Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9567-9577

  Yang, Cheng ^a,b,e   Fischer Kešo, Regina ^a,b   Schlechter, Tanja ^a,b   Ströbel, Philipp ^c   Marx, Alexander ^d   Hofmann, Ilse ^a,b  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Extracellular matrix; PKP1; Prostate cancer; SPOCK1; Testican 1

Indexed keywords

CATENIN; COLLAGENASE 3; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 8; MACROPHAGE ELASTASE; MESSENGER RNA; PLAKOPHILIN 1; PROTEIN P120; STEFIN A; UNCLASSIFIED DRUG; PKP1 PROTEIN, HUMAN; PLAKOPHILIN; PROTEOGLYCAN; SPOCK1 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; BPH 1 CELL LINE; CONTROLLED STUDY; CSTA GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HAS3 GENE; HTRA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KLK5 GENE; MALE; MMP12 GENE; MMP13 GENE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPOCK1 GENE; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOGENESIS; DISEASE COURSE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PLAKOPHILINS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RNA, MESSENGER;

EID: 84952872901     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3628-3     Document Type: Article

References (65)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.
2. Peifer M, Berg S, Reynolds AB. A repeating amino acid motif shared by proteins with diverse cellular roles. Cell. 1994;76(5):789–91.
3. Neuber S, Muhmer M, Wratten D, Koch PJ, Moll R, Schmidt A. The desmosomal plaque proteins of the plakophilin family. Dermatol Res Pract. 2010;2010:101452.
4. Garrod D, Chidgey M. Desmosome structure, composition and function. Biochim Biophys Acta. 2008;1778(3):572–87.
5. Bass-Zubek AE, Godsel LM, Delmar M, Green KJ. Plakophilins: multifunctional scaffolds for adhesion and signaling. Curr Opin Cell Biol. 2009;21(5):708–16.
6. Wolf A, Krause-Gruszczynska M, Birkenmeier O, Ostareck-Lederer A, Huttelmaier S, Hatzfeld M. Plakophilin 1 stimulates translation by promoting eIF4A1 activity. J Cell Biol. 2010;188(4):463–71.
7. Fischer-Keso R, Breuninger S, Hofmann S, Henn M, Rohrig T, Strobel P, et al. Plakophilins 1 and 3 bind to FXR1 and thereby influence the mRNA stability of desmosomal proteins. Mol Cell Biol. 2014;34(23):4244–56.
8. Sobolik-Delmaire T, Katafiasz D, Keim SA, Mahoney MG, Wahl 3rd JK. Decreased plakophilin-1 expression promotes increased motility in head and neck squamous cell carcinoma cells. Cell Commun Adhes. 2007;14(2–3):99–109.
9. Papagerakis S, Shabana AH, Depondt J, Gehanno P, Forest N. Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum Pathol. 2003;34(6):565–72.
10. Kaz AM, Luo Y, Dzieciatkowski S, Chak A, Willis JE, Upton MP, et al. Aberrantly methylated PKP1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma. Gene Chrom Cancer. 2012;51(4):384–93.
11. Schwarz J, Ayim A, Schmidt A, Jager S, Koch S, Baumann R, et al. Differential expression of desmosomal plakophilins in various types of carcinomas: correlation with cell type and differentiation. Hum Pathol. 2006;37(5):613–22.
12. Moll I, Kurzen H, Langbein L, Franke WW. The distribution of the desmosomal protein, plakophilin 1, in human skin and skin tumors. J Invest Dermatol. 1997;108(2):139–46.
13. Furukawa C, Daigo Y, Ishikawa N, Kato T, Ito T, Tsuchiya E, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res. 2005;65(16):7102–10.
14. Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, et al. The transcription factor ZEB1 (deltaEF1) represses plakophilin 3 during human cancer progression. FEBS Lett. 2007;581(8):1617–24.
15. Valladares-Ayerbes M, Diaz-Prado S, Reboredo M, Medina V, Lorenzo-Patino MJ, Iglesias-Diaz P, et al. Evaluation of plakophilin-3 mRNA as a biomarker for detection of circulating tumor cells in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1432–40.
16. Demirag GG, Sullu Y, Gurgenyatagi D, Okumus NO, Yucel I. Expression of plakophilins (PKP1, PKP2, and PKP3) in gastric cancers. Diagn Pathol. 2011;6:1.
17. Demirag GG, Sullu Y, Yucel I. Expression of plakophilins (PKP1, PKP2, and PKP3) in breast cancers. Med Oncol. 2012;29(3):1518–22.
18. Takahashi H, Nakatsuji H, Takahashi M, Avirmed S, Fukawa T, Takemura M, et al. Up-regulation of plakophilin-2 and down-regulation of plakophilin-3 are correlated with invasiveness in bladder cancer. Urology. 2012;79(1):240. e1–8.
19. Yang C, Strobel P, Marx A, Hofmann I. Plakophilin-associated RNA-binding proteins in prostate cancer and their implications in tumor progression and metastasis. Virchows Arch. 2013;463(3):379–90.
20. Breuninger S, Reidenbach S, Sauer CG, Strobel P, Pfitzenmaier J, Trojan L, et al. Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol. 2010;176(5):2509–19.
21. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010;339(1):237–46.
22. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61(2):198–223.
23. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697–706.
24. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16(5):558–64.
25. Bode W, Huber R. Proteinase-protein inhibitor interaction. In: Sies H, Flohé L, Zimmer G, editors. Molecular aspects of inflammation. Colloquium der gesellschaft für biologische chemie 11–13 April 1991 in Mosbach/Baden. Heidelberg: Springer Berlin; 1991. p. 103–15.
26. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(Pt 24):4195–200.
27. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012;44(3):480–8.
28. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11(6):231–46.
29. Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, et al. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 2013;144(1):179–91. e4.
30. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol. 2009;22(2):261–72.
31. Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, et al. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene. 2014;33(25):3334–41.
32. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Muller M, et al. Downregulation of several fibulin genes in prostate cancer. Prostate. 2007;67(16):1770–80.
33. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
34. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995;31(1):14–24.
35. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
36. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.
37. Krojer T, Garrido-Franco M, Huber R, Ehrmann M, Clausen T. Crystal structure of DegP (HtrA) reveals a new protease-chaperone machine. Nature. 2002;416(6879):455–9.
38. Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001;382(1):5–14.
39. Rawlings ND, Tolle DP, Barrett AJ. Evolutionary families of peptidase inhibitors. Biochem J. 2004;378(Pt 3):705–16.
40. Bobek LA, Levine MJ. Cystatins—inhibitors of cysteine proteinases. Crit Rev Oral Biol Med. 1992;3(4):307–32.
41. Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life. 2002;54(4):195–9.
42. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
43. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
44. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80.
45. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.
46. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101(3):811–6.
47. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
48. Green KJ, Simpson CL. Desmosomes: new perspectives on a classic. J Invest Dermatol. 2007;127(11):2499–515.
49. Dusek RL, Attardi LD. Desmosomes: new perpetrators in tumour suppression. Nat Rev Cancer. 2011;11(5):317–23.
50. Chidgey M, Dawson C. Desmosomes: a role in cancer? Br J Cancer. 2007;96(12):1783–7.
51. van Leenders GJ, Aalders TW, de Kaa CA H-v, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol. 2001;195(5):563–70.
52. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, et al. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol. 1992;421(2):157–61.
53. Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, et al. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res. 2011;317(2):234–47.
54. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395–406.
55. Alliel PM, Perin JP, Jolles P, Bonnet FJ. Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem. 1993;214(1):347–50.
56. Wight TN, Kinsella MG, Qwarnstrom EE. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol. 1992;4(5):793–801.
57. Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 2010;277(19):3876–89.
58. Edgell CJ, BaSalamah MA, Marr HS. Testican-1: a differentially expressed proteoglycan with protease inhibiting activities. Int Rev Cytol. 2004;236:101–22.
59. Bocock JP, Edgell CJ, Marr HS, Erickson AH. Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L. Eur J Biochem. 2003;270(19):4008–15.
60. Marr HS, Edgell CJ. Testican-1 inhibits attachment of Neuro-2a cells. Matrix Biol. 2003;22(3):259–66.
61. Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y. SPOCK1 is a novel transforming growth factor-β target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2013;440(4):792–7.
62. Pieters T, van Roy F, van Hengel J. Functions of p120ctn isoforms in cell-cell adhesion and intracellular signaling. Front Biosci. 2012;17:1669–94.
63. Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J. 2012;31(12):2714–36.
64. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
65. Aparicio LA, Abella V, Valladares M, Figueroa A. Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell Mol Life Sci. 2013;70(23):4463–77.